GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Cyclically Adjusted Price-to-FCF

Zeo ScientifiX (Zeo ScientifiX) Cyclically Adjusted Price-to-FCF : (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zeo ScientifiX Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Zeo ScientifiX's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Cyclically Adjusted Price-to-FCF Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.10

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.12 0.20 0.10 -

Competitive Comparison of Zeo ScientifiX's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Zeo ScientifiX's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Cyclically Adjusted Price-to-FCF falls into.



Zeo ScientifiX Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Zeo ScientifiX's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Zeo ScientifiX's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0/129.4194*129.4194
=0.000

Current CPI (Jan. 2024) = 129.4194.

Zeo ScientifiX Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 -0.003 100.023 -0.004
201407 -0.008 100.520 -0.010
201410 -0.028 100.176 -0.036
201501 -0.009 98.604 -0.012
201504 -0.008 99.824 -0.010
201507 -0.122 100.691 -0.157
201510 -0.688 100.346 -0.887
201601 -0.272 99.957 -0.352
201604 -0.473 100.947 -0.606
201607 -0.245 101.524 -0.312
201610 -0.108 101.988 -0.137
201701 -0.092 102.456 -0.116
201704 -1.404 103.167 -1.761
201707 -0.286 103.278 -0.358
201710 0.065 104.070 0.081
201801 -0.116 104.578 -0.144
201804 -0.267 105.708 -0.327
201807 -0.064 106.324 -0.078
201810 -0.067 106.695 -0.081
201901 -0.014 106.200 -0.017
201904 -0.099 107.818 -0.119
201907 -0.050 108.250 -0.060
201910 -0.077 108.577 -0.092
202001 -0.121 108.841 -0.144
202004 -0.141 108.173 -0.169
202007 -0.112 109.318 -0.133
202010 -0.190 109.861 -0.224
202101 -0.109 110.364 -0.128
202104 -0.216 112.673 -0.248
202107 -0.124 115.183 -0.139
202110 -0.136 116.696 -0.151
202201 -0.135 118.619 -0.147
202204 -0.055 121.978 -0.058
202207 -0.168 125.002 -0.174
202210 -0.279 125.734 -0.287
202301 -0.001 126.223 -0.001
202304 178.507 127.992 180.498
202307 -0.066 128.974 -0.066
202310 0.029 129.810 0.029
202401 0.000 129.419 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zeo ScientifiX  (OTCPK:ZEOX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Zeo ScientifiX Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140